{"id":1783,"date":"2014-03-18T12:48:42","date_gmt":"2014-03-18T12:48:42","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=1783"},"modified":"2014-03-18T12:48:42","modified_gmt":"2014-03-18T12:48:42","slug":"duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\/","title":{"rendered":"Duale Pl\u00e4ttchenhemmung: ist die Zeit reif f\u00fcr ein Therapiemonitoring?"},"content":{"rendered":"<p>AMB 2011,\u00a045, 33 &nbsp; Duale Pl\u00e4ttchenhemmung: ist die Zeit reif f\u00fcr ein Therapiemonitoring? &nbsp; Zusammenfassung: Ergebnisse einer monozentrischen Studie (5) zeigen, dass nach Anlage eines koronaren Stents bei 41,7% der Patienten die Aggregation der Thrombozyten mit der Standardtherapie (100\u00a0mg\/d ASS plus 75\u00a0mg\/d Clopidogrel) unzureichend gehemmt ist. Jeder Dritte hat in einem Thrombozytenfunktionstest eine verminderte Clopidogrel- [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2011,\u00a045, 33 &nbsp; Duale Pl\u00e4ttchenhemmung: ist die Zeit reif f\u00fcr ein Therapiemonitoring? &nbsp; Zusammenfassung: Ergebnisse einer monozentrischen Studie (5) zeigen, dass nach Anlage eines koronaren Stents bei 41,7% der Patienten die Aggregation der Thrombozyten mit der Standardtherapie (100\u00a0mg\/d ASS plus 75\u00a0mg\/d Clopidogrel) unzureichend gehemmt ist. Jeder Dritte hat in einem Thrombozytenfunktionstest eine verminderte Clopidogrel- [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[199,926],"tags":[128,75,76,643,129,927,139,928,78,79,74,85,324,106,644,148],"class_list":["post-1783","post","type-post","status-publish","format-standard","hentry","category-jahr-2011-band-45","category-monat-5","tag-acetylsalicylsaeure","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-aspirin-resistenz","tag-azetylsalizylsaeure","tag-bocla-plan","tag-clopidogrel","tag-gravitas-studie","tag-herzinfarkt","tag-koronare-herzkrankheit","tag-myokardinfarkt","tag-prasugrel","tag-stent","tag-thrombozytenaggregationshemmer","tag-ticlopidin","tag-triton-timi-38-studie"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Duale Pl\u00e4ttchenhemmung: ist die Zeit reif f\u00fcr ein Therapiemonitoring?<\/title>\n<meta name=\"description\" content=\"Ergebnisse einer monozentrischen Studie (5) zeigen, dass nach Anlage eines ...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Duale Pl\u00e4ttchenhemmung: ist die Zeit reif f\u00fcr ein Therapiemonitoring?\" \/>\n<meta property=\"og:description\" content=\"Ergebnisse einer monozentrischen Studie (5) zeigen, dass nach Anlage eines ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2014-03-18T12:48:42+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"7\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"Duale Pl\u00e4ttchenhemmung: ist die Zeit reif f\u00fcr ein Therapiemonitoring?\",\"datePublished\":\"2014-03-18T12:48:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\\\/\"},\"wordCount\":1394,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"keywords\":[\"Acetylsalicyls\u00e4ure\",\"Akutes Koronarsyndrom\",\"Angina pectoris\",\"Aspirin-Resistenz\",\"Azetylsalizyls\u00e4ure\",\"BOCLA-Plan\",\"Clopidogrel\",\"GRAVITAS-Studie\",\"Herzinfarkt\",\"Koronare Herzkrankheit\",\"Myokardinfarkt\",\"Prasugrel\",\"Stent\",\"Thrombozytenaggregationshemmer\",\"Ticlopidin\",\"TRITON-TIMI 38-Studie\"],\"articleSection\":[\"Jahr 2011 Band 45\",\"Monat 5\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\\\/\",\"name\":\"Duale Pl\u00e4ttchenhemmung: ist die Zeit reif f\u00fcr ein Therapiemonitoring?\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"datePublished\":\"2014-03-18T12:48:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"description\":\"Ergebnisse einer monozentrischen Studie (5) zeigen, dass nach Anlage eines ...\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Duale Pl\u00e4ttchenhemmung: ist die Zeit reif f\u00fcr ein Therapiemonitoring?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Duale Pl\u00e4ttchenhemmung: ist die Zeit reif f\u00fcr ein Therapiemonitoring?","description":"Ergebnisse einer monozentrischen Studie (5) zeigen, dass nach Anlage eines ...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\/","og_locale":"de_DE","og_type":"article","og_title":"Duale Pl\u00e4ttchenhemmung: ist die Zeit reif f\u00fcr ein Therapiemonitoring?","og_description":"Ergebnisse einer monozentrischen Studie (5) zeigen, dass nach Anlage eines ...","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2014-03-18T12:48:42+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"7\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"Duale Pl\u00e4ttchenhemmung: ist die Zeit reif f\u00fcr ein Therapiemonitoring?","datePublished":"2014-03-18T12:48:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\/"},"wordCount":1394,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","keywords":["Acetylsalicyls\u00e4ure","Akutes Koronarsyndrom","Angina pectoris","Aspirin-Resistenz","Azetylsalizyls\u00e4ure","BOCLA-Plan","Clopidogrel","GRAVITAS-Studie","Herzinfarkt","Koronare Herzkrankheit","Myokardinfarkt","Prasugrel","Stent","Thrombozytenaggregationshemmer","Ticlopidin","TRITON-TIMI 38-Studie"],"articleSection":["Jahr 2011 Band 45","Monat 5"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\/","name":"Duale Pl\u00e4ttchenhemmung: ist die Zeit reif f\u00fcr ein Therapiemonitoring?","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","datePublished":"2014-03-18T12:48:42+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"description":"Ergebnisse einer monozentrischen Studie (5) zeigen, dass nach Anlage eines ...","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Duale Pl\u00e4ttchenhemmung: ist die Zeit reif f\u00fcr ein Therapiemonitoring?"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=1783"}],"version-history":[{"count":1,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1783\/revisions"}],"predecessor-version":[{"id":1784,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1783\/revisions\/1784"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=1783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=1783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=1783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}